In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aeolus Pharmaceuticals Inc.

www.aeoluspharma.com

Latest From Aeolus Pharmaceuticals Inc.

Deals Shaping The Medical Industry, January 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2015.

BioPharmaceutical Medical Device

Vesta Therapeutics Inc.

Hopes to develop a donor organ-sparing treatment for liver disease and liver failure.
BioPharmaceutical Regenerative Medicine

Redefining the Stem Cell Opportunity

Small companies are now trying to leverage the value of both embryonic stem cells and adult stem cells, as genomics tools and for toxicology screening. At the same time, stem cells are gradually making their way into human testing, leading to an even more urgent need to understand the role that cytokines and growth factors play in signaling cells to differentiate. In fact, there's a growing recognition that the ultimate pharma opportunity may lie in selling drug cocktails that control cell differentiation, not in making and selling cells. Because dormant adult stem cells reside in tissues and in circulation, researchers are even beginning to envision applications where transplanted replacement cells are not needed at all.
BioPharmaceutical Manufacturing

Skyepharma:Trying To Take Off From a Short Runway

Since 1998, through a series of inexpensive acquisitions, SkyePharma has assembled a wide range of drug delivery technologies, positioning itself as a one stop shop. But the company still has to convince both its customers, and its investors, that it has not sacrificed quality for quantity.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Incara Pharmaceuticals Corp.
  • Intercardia Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Aeolus Pharmaceuticals Inc.
  • Senior Management
  • John L McManus, Pres. & CEO
    David L Cavalier, CFO
    Brian J Day, PhD, CSO
    Christopher Stanley, VP, Ops
  • Contact Info
  • Aeolus Pharmaceuticals Inc.
    Phone: (949) 481-9825
    26361 Crown Valley Parkway
    Suite 150
    Mission Viejo, CA 92691
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register